



## **Intelligence Renaissance Industries**

### **Our Product Suite Today and Going Forward**

#### **Tailored to Our Clients, Customers, Sponsors, Investors, Partners**

Our company provides critical health and safety solutions for communities and institutions. We integrate antimicrobial bioprotection of facilities and equipment, with mobile diagnostic and analytical labs, with public and provider education and resource management. We are also engaged in development of a novel class of antiviral medicines with both preventive and therapeutic power.

We are looking to you to be our partner as we move forward to improve our world's strength and resilience to emergencies and challenges such as we have all seen, worldwide, with COVID-19. One community, one region, at a time. With the right partners, we can achieve what we all need, Together. With the right partners, everyone gains, including with the very important advantage of gaining new market trust and confidence.

We describe here four of our integrated products, three of which are in-market. The fourth, research underway now that is approaching readiness for clinical trials, is an antiviral medicine that will be introduced first for COVID and later for a broad range of other viral diseases. Our company and our scientific and medical partners constitute the most unique and unparalleled Team that has ever been assembled, hand-picked, incredibly synergetic and symbiotic, and Able to Build and Do what Our World Needs.

### **BIOPROT**

Our BioProt™ comprehensive antimicrobial bioprotection protocol is the most effective program of protecting people from surface-contact contagion and close-contact transmission. Through our analytics and process-change engineering, we create for the client the optimal ways for people to interact with each other and with facilities, instruments, equipment, and materials including textiles and other contact-fabrics. With the physical bioprotectant technology, BioProt™ secures all contactable surfaces on a long-term to virtually permanent basis against not only COVID-19 but other bacteria, viruses, molds, and fungi, resisting successfully the possibilities of surface-contact transmission and infection. Our BioProt™ solution enables schools, universities, the entire travel and hotel industry, food producers, social establishments, athletic facilities and sporting arenas, and many other companies and institutions, to open and operate with greater safety and security than ever before. This program of treatment, complete with facility and equipment biosafety analysis, is coupled with proactive education and training for staff, clients and visitors. Bioprot™ is the only such program available that combines surface and material bioprotection with requisite professional analytics and informatics, providing a reliable, sustainable solution for the major pathway of infection with many bio pathogens including the SARS-CoV-2 virus responsible for COVID-19.

### **MEDATRIUM**

Our MedAtrium™ mobile diagnostic laboratory units provide the most robust facility available for bringing multiple, complementary diagnostic tests together in one comfortable and highly portable structure. MedAtrium enables rapid (same-day) diagnosis of COVID-19 and many other biopathogens (influenza, norovirus, salmonella, e.coli, c-difficile, staph-aureus, and many rare types). In addition, simultaneously, MedAtrium™ provides

diagnostic testing for select comorbidities and associated medical conditions faced by individuals exposed to the SARS-CoV-2 virus, influenza viruses and/or several other pathogens. We particularly emphasize the detection, diagnosis and risk analysis for cardiovascular and pulmonary factors. For instance, myocarditis is a significant concern for many viral infections and especially asymptomatic COVID-19.

Our employment of the latest diagnostics such as single-molecule analysis (SIMOA) enables our RT-PCR based nucleic acid diagnosis to drastically reduce the incidence of false positives and false negatives, in addition to enabling the additional “no extra effort” testing for several rare but potentially life-threatening neurological, endocrine, and cardiovascular disorders.

MedAtrium™ is available to institutions including hospitals, public health agencies and companies worldwide and is delivered with full setup, training, and services. The units come in two sizes with two and three specialized compartments respectively, and the labs are available for purchase, lease or on a time-sharing basis.

## **EYRIE**

Each MedAtrium unit and each BioProt-enabled facility serve, along with many other hospitals, medical centers, research universities, and local/state/governmental health departments, as nodes in a global network of diagnostic, therapeutic and major-clinical centers linked together through the Eyrie™ epidemiological informatics network which provides the public and health authorities with rapid real-time information on infection tracing and tracking, social distancing breakdowns, emerging mutation possibilities, and availability of critical medical resources and supplies including medications.

Eyrie™ integrates tracing and tracking for epidemiological incidents and outbreaks as well as critical PPE, assay, ventilator and other medical supply resource availability and optimization for routing and sharing of such critical resources. It incorporates synthetic intelligence (“SI”) computational methods along with versatile ways to both acquire accurate public and “crowdsourced” data and to deliver responsible, privacy-assuring information to people as citizens, patients, providers, and administrators.

## **VESID**

Our VESID™ research program in antiviral medicine development has attained phase 2 level as we proceed into our next round of clinical modeling and simulation stages prior to in-vivo experimentation and testing. VESID is a novel approach to addressing the containment and reduction of COVID-19 and other respiratory-tract viral diseases, based upon original research conducted by IRI and partners in four universities and medical centers. VESID is not a vaccine nor a last-resorts medication but a combination of prophylactic and therapeutic treatment aimed at reducing COVID-19 infections, and the research points strongly to application of the fundamental model and architecture of this drug design for other viral pathogens in the future.

Contact:

Rachael L. Csencsits, Chief of Operations rachaelc@intelrenaissance.com +1 (562) 399-2890

[www.intelrenaissance.com](http://www.intelrenaissance.com)